EMA/166242/2018
ENCePP Code of Conduct Revision 4

European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

Declaration of compliance with the ENCePP Code of Conduct

The (primary) lead investigator and a person authorised to sign on behalf of the coordinating study entity hereby declare[1] for the purpose of conducting the study *<include here study name and identifier/registration no.>*: Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine - CLARION/EUPAS 24484

- to follow the rules and principles for the independent and transparent conduct of pharmacoepidemiological and pharmacovigilance studies of the current version of the ENCePP Code of Conduct[2];
- to inform the ENCePP Secretariat, of any change or decision to change that constitutes a deviation from the provisions of this Code.

It is of note that the (primary) lead investigator and the person authorised to sign on behalf of the coordinating study entity may be identical.

Name of (primary) lead investigator: Irene Bezemer

Date: 11/06/2021 (dd/mm/yyyy)

Stamp (if applicable) and signature: DocuSigned by: Irene Bezemer 5CD5EBAD84FB43C...

Name of the coordinating study entity: IQVIA Real World Solutions (former EPID Research)

Address:

Metsänneidonkuja 6
02130 Espoo
Finland

Name of person authorised to sign on behalf of the coordinating study entity [if different from (primary) lead investigator]: Riku Kivimäki

Date: 16/06/2021 (dd/mm/yyyy)

DocuSigned by: Riku Kivimäki 4BB43AD2E89145F...

Stamp (if applicable) and signature:

The (primary) lead investigator should also complete, sign and date the Checklist of the ENCePP Code of Conduct.

[1] Complete the declaration on screen, then print and scan a signed and stamped (if applicable) copy.
[2] Adopted Code and any revision thereof at the time of signature of the declaration.